A correction from source is issued for the news release of even date. The news release has been corrected for the Warrant and Finder Warrant exercise prices. The corrected release follows:  NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH US NEWSWIRE SERVICES  VANCOUVER, British Columbia, July 11, 2019 (GLOBE

VANCOUVER, British Columbia, June 18, 2019 (GLOBE NEWSWIRE) — Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) (“Avricore Health” or the “Company”) announces today additions and changes to its board and executive team as the Company continues to align itself for further growth in the year ahead. Sherif Guorgui is leaving the Board of

Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) (“Avricore Health” or the “Company”) is pleased to announce a non-brokered private placement of up to 21,428,571 units of the Company (the “Units”) at a price of $0.07 per Unit for aggregate gross proceeds of up to $1,500,000 (the “Private Placement”). Each Unit

Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) (“Avricore Health”or the “Company”) reports that the Management Cease Trade Order granted by the British Columbia Security Commission on May 2, 2019 was lifted effective June 3, 2019 following the filing of the Company’s financial statements and accompanying management’s discussion and analysis for

Kevin Strong will serve as CFO and Deena Siblock takes on Corporate Secretary role, adding capacity and talent to the fast-growing healthcare technology leader, Avricore Health. Vancouver, May XX, 2019 – Avricore Health Inc. (TSXV: AVCR) (OTCBB: AVCR) (“Avricore Health”) is expanding its capacity to meet its objectives by adding

Avricore Health Inc. (TSXV:  AVCR) (“Avricore Health”) has signed a distribution agreement with Molecular You Corporation (“Molecular You”) to provide its newly developed genetic medication response test myCannabisPGxTM, which is designed to ensure safe and effective use of medical cannabis in a community pharmacy setting. During this launch phase, Avricore

Avricore Health offers products and services to empower and educate pharmacists   Government action on drug pricing has had unintended consequences for community pharmacies and health care Avricore Health’s offering helps pharmacists grow revenues, enhance role in customer care HealthTabTM allows quick access to health biomarkers, personalized genomic information The Government

Government action on drug pricing has had unintended consequences for community pharmacies and healthcare Avricore Health’s offering helps pharmacists grow revenues, enhance role in customer care HealthTab™ allows quick access to health biomarkers, personalized genomic information The Government of Canada’s recent actions to take costs out of the health care

Avricore Health Inc. Advisory Board Welcomes Mark Zhou Pharmacy practice specialist and McKesson representative brings talent and expertise to Avricore’s strategic development and client education team Vancouver, March 18, 2019 (GLOBE NEWSWIRE) — Avricore Health Inc. (TSXV: AVCR) (“Avricore Health”) is very pleased to announce that Mark Zhou will join

March 15, 2019 – Avricore Health Inc. (“AVCR”), is pleased to announce that further to its news release dated February 13, 2019, it has closed a non-brokered private placement of 4,206,435 common shares (“Common Shares”) of the Company at a price of $0.07 per Common Share for gross proceeds of